Heart Failure in Men: What It Is, Why It Happens, and What to Expect

He used to walk upstairs without thinking about it. Now he has to pause at the landing. His ankles have been swollen for weeks, but he assumed it was from long days on his feet. He gets winded carrying groceries to the car. He’s been sleeping on two pillows for months because lying flat makes him feel like he cannot catch his breath, but he never mentioned it to his doctor because he figured it was just getting older.

This is how heart failure often presents in men: gradually, quietly, and with a set of symptoms that are easy to rationalize as something else. By the time a man reaches a cardiologist, his heart may have been struggling for months or years. Heart failure is not a condition that announces itself with the drama of a heart attack. It accumulates. And in men, the trajectory from early dysfunction to overt symptoms often goes unrecognized until the disease is substantially advanced.

What Heart Failure Actually Means

Heart failure does not mean the heart has stopped working. It means the heart is failing to meet the body’s demands for blood flow, either because the muscle is too weak to pump adequately, or because it is too stiff to fill adequately, or both. The result, in either case, is inadequate cardiac output for activity and a backup of fluid pressure that the heart cannot move forward efficiently.

This backup of pressure is responsible for most of the symptoms men experience. When the left ventricle cannot empty or fill properly, pressure rises in the left atrium, then in the pulmonary veins, then in the lung capillaries. Fluid leaks from those capillaries into the lung tissue, producing pulmonary congestion and the breathlessness that is the hallmark symptom of heart failure. When the right side of the heart is also under strain, fluid backs up into the systemic veins, producing the ankle swelling, leg edema, and abdominal distension that are classic signs of right-sided congestion.

Heart failure is categorized primarily by ejection fraction, which is the percentage of blood the left ventricle ejects with each heartbeat. This number is measured on echocardiography and is the single most important variable in determining treatment.

HFrEF vs HFpEF: Two Conditions, One Name

Heart failure with reduced ejection fraction (HFrEF) is defined as heart failure in which the ejection fraction is below 40%. The heart muscle in HFrEF is typically dilated and weakened. The left ventricle enlarges in an attempt to compensate for its reduced contractility, but this remodeling is ultimately maladaptive, increasing wall stress and driving further deterioration. The majority of men with heart failure have HFrEF, particularly those with a prior history of heart attack.

Heart failure with preserved ejection fraction (HFpEF) is defined as heart failure in which the ejection fraction is 50% or above (mildly reduced is defined as 40 to 49%, often abbreviated HFmrEF). In HFpEF, the heart muscle is stiff and cannot relax properly between beats, impairing its ability to fill with blood during diastole. Despite an apparently normal squeeze, the stiff ventricle fills at high pressures, and those elevated filling pressures back up into the lungs and produce the same congestion symptoms as HFrEF.

The clinical importance of this distinction is profound. HFrEF has a substantial, evidence-based pharmacological treatment framework with four medication classes that independently reduce mortality. HFpEF, by contrast, proved frustrating to treat for decades, with most trials failing to show mortality benefit; more recent data with SGLT2 inhibitors has changed the landscape modestly but meaningfully.

Men are more likely than women to develop HFrEF, primarily because ischemic cardiomyopathy following myocardial infarction is more common in men. Women are more likely to develop HFpEF. Men also develop heart failure roughly 10 years earlier than women on average, reflecting their earlier onset of coronary artery disease and hypertension-related cardiac damage.

Common Causes in Men

Ischemic cardiomyopathy is the most common cause of HFrEF in men. When a significant area of myocardium is permanently damaged by myocardial infarction, that territory is replaced by scar tissue that cannot contract. The surviving muscle must compensate, but compensation has limits. Over months to years, the surviving muscle undergoes adverse remodeling, the ventricle dilates, the ejection fraction falls, and clinical heart failure emerges. Men who have survived a large MI, particularly one involving the LAD territory, should be monitored with regular echocardiography for the development of systolic dysfunction even if they are asymptomatic.

Hypertensive heart disease develops when chronically elevated blood pressure forces the left ventricle to work against higher resistance over years. The initially adaptive thickening of the ventricular wall (concentric hypertrophy) eventually gives way to diastolic dysfunction and, in some cases, systolic dysfunction. Poorly controlled hypertension is a major contributor to both HFrEF and HFpEF in men.

Alcohol cardiomyopathy is an underappreciated cause in men and is directly related to cumulative alcohol exposure. Chronic heavy alcohol consumption, generally defined as more than 80 grams of pure alcohol per day for years, is directly toxic to cardiomyocytes. The result is a dilated cardiomyopathy that can be clinically indistinguishable from idiopathic dilated cardiomyopathy on echocardiography. The critical distinguishing feature is reversibility: complete alcohol cessation can produce substantial, sometimes dramatic, recovery of ejection fraction in some men within 6 to 12 months. Identifying alcohol as the causative agent changes the management entirely, because the most effective treatment is abstinence.

Idiopathic dilated cardiomyopathy, in which no specific cause can be identified, is more common in men and frequently has a genetic component. Pathogenic variants in genes such as TTN (encoding titin, the giant sarcomeric protein), LMNA (encoding lamin A/C), and several others are found in roughly 25 to 35% of patients with apparently sporadic dilated cardiomyopathy. Genetic counseling and family screening are appropriate in men diagnosed with dilated cardiomyopathy without an identified cause.

Valvular heart disease, particularly aortic stenosis (progressive calcification and narrowing of the aortic valve) and mitral regurgitation (leakage of the mitral valve), can produce heart failure through distinct mechanisms. Aortic stenosis imposes a pressure overload on the left ventricle; mitral regurgitation imposes a volume overload. Both can eventually overwhelm the ventricle’s compensatory capacity and lead to systolic dysfunction.

Chemotherapy-related cardiomyopathy is increasingly recognized as anthracyclines (doxorubicin, epirubicin), trastuzumab (Herceptin), and other cardiotoxic agents are used more widely for cancer treatment. Men treated for testicular cancer, lymphoma, or other malignancies with these agents warrant baseline and follow-up echocardiographic surveillance.

Symptoms: What Men Experience and Why They Wait

The symptom that typically appears first in men with developing heart failure is exertional dyspnea, breathlessness that appears with physical activities that were previously well-tolerated. Because this symptom develops gradually over months, men commonly attribute it to deconditioning, weight gain, aging, or a respiratory issue rather than to cardiac pathology. The absence of chest pain, which men tend to associate with heart problems, reinforces the misattribution.

Orthopnea is the inability to lie flat without becoming breathless. It occurs because lying flat redistributes fluid from the legs and abdomen into the central circulation, increasing pulmonary venous pressure. Men who have been sleeping on multiple pillows for months without mentioning it are describing orthopnea, and this symptom is highly specific for elevated left-sided filling pressures.

Paroxysmal nocturnal dyspnea, waking suddenly from sleep with severe breathlessness, is another highly specific symptom. Men are sometimes frightened by this symptom but chalk it up to a nightmare or a panic attack. It represents acute pulmonary edema in the supine position and should prompt urgent evaluation.

Ankle and leg edema, typically worse at the end of the day and improved in the morning after a night of elevation, reflects elevated right-sided filling pressures and fluid retention. Combined with exertional dyspnea, bilateral ankle edema in a man in his 50s or 60s should raise heart failure as a leading diagnosis until proven otherwise.

Fatigue and reduced exercise tolerance are common but non-specific. Men with heart failure often describe feeling like they “run out of energy” faster than they used to. This reflects reduced cardiac output and the activation of neurohormonal compensatory systems, including the renin-angiotensin-aldosterone system and sympathetic activation, both of which produce fatigue as side effects.

NYHA Classification: Quantifying Functional Impairment

The New York Heart Association functional classification system is a standard way to describe symptom severity in heart failure and is used to guide treatment decisions.

Class I denotes no symptoms with ordinary activity; heart failure is present on objective testing but the patient is functionally unlimited. Class II indicates mild symptoms with moderate exertion, such as climbing two flights of stairs or walking briskly uphill, with comfortable rest. Class III involves symptoms with minimal exertion, including walking on level ground at a slow pace, with comfortable rest but significant functional limitation. Class IV denotes symptoms at rest or with any physical activity, with severe functional impairment.

Most men first seek care in NYHA Class II or III, often after months of gradually worsening Class II symptoms that they minimized. Men who present at Class IV, with symptoms at rest, often require hospitalization for initial stabilization.

Guideline-Directed Medical Therapy for HFrEF: The Four Pillars

For men with HFrEF, guideline-directed medical therapy (GDMT) is the most important intervention available and represents a remarkable therapeutic advance over the past three decades. Four classes of medications have individually demonstrated mortality benefit in large randomized controlled trials and together produce additive survival benefit.

The first pillar is inhibition of the renin-angiotensin system. ACE inhibitors (enalapril, lisinopril, ramipril) were the first agents to demonstrate mortality reduction in HFrEF, and ARBs (valsartan, losartan, candesartan) are alternatives for patients intolerant of ACE inhibitors due to cough. Both classes reduce afterload, diminish neurohormonal activation, and slow adverse cardiac remodeling. For men who can tolerate it, sacubitril-valsartan (brand name Entresto) has replaced ACE inhibitor or ARB monotherapy as the preferred agent.

The PARADIGM-HF trial, comparing sacubitril-valsartan to enalapril in patients with HFrEF, demonstrated a 20% reduction in the primary composite of cardiovascular death or heart failure hospitalization, and a 20% reduction in all-cause mortality. This trial established sacubitril-valsartan as the preferred renin-angiotensin system agent in eligible patients with HFrEF.

The second pillar is beta-blockade. Three specific beta-blockers have demonstrated mortality benefit in HFrEF: carvedilol, metoprolol succinate, and bisoprolol. These agents counteract the chronic sympathetic nervous system activation that occurs in heart failure and that, while initially compensatory, ultimately drives further myocardial damage. Beta-blockers improve ejection fraction, reduce sudden cardiac death, and improve functional capacity over months of use. They must be initiated at low doses and uptitrated gradually in clinically stable patients.

The third pillar is mineralocorticoid receptor antagonism. Spironolactone and eplerenone block the effects of aldosterone, which is chronically elevated in heart failure and contributes to sodium retention, myocardial fibrosis, and ventricular remodeling. Both agents reduce mortality and hospitalization in HFrEF and are recommended for men with persistent symptoms on ACE inhibitor/ARB and beta-blocker therapy. Monitoring of potassium levels is required, particularly in men with chronic kidney disease.

The fourth pillar is SGLT2 inhibition. Originally developed as glucose-lowering agents for diabetes, SGLT2 inhibitors were found to produce striking cardiovascular benefits in men both with and without diabetes.

The DAPA-HF trial evaluated dapagliflozin in patients with HFrEF, including a substantial proportion without diabetes. Dapagliflozin reduced the primary composite endpoint of cardiovascular death, worsening heart failure, or hospitalization by 26% relative risk reduction compared with placebo. The benefit was consistent across diabetic and non-diabetic patients, establishing SGLT2 inhibitors as a foundational HFrEF therapy independent of glycemic status. Empagliflozin demonstrated similar benefits in the EMPEROR-Reduced trial.

The practical target for every man with HFrEF is to be on all four pillars at target doses. Studies using models of expected benefit suggest that simultaneous initiation at even modest doses produces greater early mortality reduction than the traditional sequential uptitration approach, and some cardiologists now advocate for early quadruple therapy initiation in appropriate patients.

Device Therapy: When Medications Are Not Enough

For men with HFrEF that remains severely impaired despite adequate GDMT, device therapy offers additional mortality benefit.

An implantable cardioverter-defibrillator (ICD) is indicated for men with an ejection fraction below 35% who have been on optimal GDMT for at least three months. Sudden cardiac death from ventricular arrhythmia is a major cause of mortality in HFrEF, and the ICD prevents this mechanism by delivering a shock to terminate life-threatening arrhythmias. Guidelines recommend waiting three months on maximal GDMT before implanting an ICD, because ejection fraction often improves substantially with improved medical therapy.

Cardiac resynchronization therapy (CRT) is indicated for men with an ejection fraction below 35% who also have a left bundle branch block (LBBB) pattern on ECG with a QRS duration above 150 milliseconds. In these men, the two ventricles are contracting out of sync, further reducing cardiac efficiency. CRT delivers coordinated pacing to both ventricles, restoring synchrony and improving ejection fraction, symptoms, and survival in appropriate patients.

Decompensated Heart Failure: Managing Acute Episodes

Despite optimal management, some men with heart failure develop episodes of acute decompensation, in which fluid retention and congestion worsen to the point of requiring hospitalization. The cardinal symptom is worsening dyspnea, often with marked decline in exercise capacity and new or worsening orthopnea.

In-hospital management centers on decongestion with intravenous diuretics. IV furosemide is the most commonly used agent and can produce rapid relief of pulmonary and peripheral congestion. Careful monitoring of fluid balance, electrolytes, and renal function is essential, as aggressive diuresis can cause acute kidney injury and electrolyte abnormalities.

A critical principle of decompensated HF management that has emerged from evidence is the importance of not stopping GDMT during hospitalization. Unless the patient is hemodynamically unstable (hypotensive or in cardiogenic shock), GDMT should be continued at the same or reduced doses rather than discontinued. Stopping medications during admission removes their neurohormonal blocking effect at a vulnerable moment.

Early follow-up after discharge, ideally within 7 days, is associated with reduced 30-day readmission rates. The transition from hospital to outpatient care is a high-risk period, and many decompensations within weeks of discharge are driven by medication errors, dietary indiscretion (high sodium intake), or insufficient diuretic adjustment.

HFpEF in Men: A Different Challenge

While HFpEF is more common in women, it does occur in men, particularly in the setting of hypertension, obesity, and diabetes. The management of HFpEF in men has historically lacked the strong evidence base that exists for HFrEF.

The most important interventions for HFpEF with strong evidence include rigorous blood pressure control, which slows the progression of diastolic dysfunction; weight loss in obese men, which reduces filling pressures and improves functional capacity; and SGLT2 inhibitors, which showed modest but statistically significant outcome benefit in both the EMPEROR-Preserved and DELIVER trials, establishing the first pharmacological therapy with evidence-based benefit in HFpEF.

Exercise training, contrary to the intuition that men with heart failure should rest, is supported by evidence from trials showing improved functional capacity and quality of life with supervised exercise programs in HFpEF. The mechanism likely involves improved skeletal muscle oxygen extraction and peripheral vascular adaptation rather than direct cardiac remodeling.

Prognosis: The Modern Picture

The prognosis of heart failure has improved dramatically over the past three decades, driven primarily by the sequential introduction of the four GDMT pillars. A man diagnosed with HFrEF and optimally treated with all four agents today faces a meaningfully better five-year survival than was possible in the 1990s with ACE inhibitors alone.

Current estimates suggest five-year survival for optimally treated HFrEF in the range of 50 to 60%, a number that continues to improve as quadruple therapy becomes more widely implemented and as device therapy is used appropriately. The trajectory is toward continued improvement as additional agents are studied and as earlier diagnosis allows intervention before severe remodeling has occurred.

The most important determinants of prognosis in an individual man with heart failure include the severity of baseline ejection fraction impairment, the presence or absence of ischemic etiology, comorbidities such as chronic kidney disease and diabetes, and, critically, the completeness of GDMT implementation. A man with an ejection fraction of 25% who is on all four pillars at target doses has a substantially better outlook than a man with the same ejection fraction who is on a beta-blocker alone.

What Men Need to Understand About Their Own Risk

The demographic reality is that men develop heart failure earlier, more often due to ischemic causes, and with a greater tendency toward the reduced-ejection-fraction variant that requires aggressive multi-drug therapy. The lifestyle contributors that are more prevalent in men, including heavy alcohol use, higher rates of uncontrolled hypertension, delayed medical care-seeking, and post-MI inadequate follow-up, all contribute to this pattern.

Heart failure is not an endpoint. It is a chronic condition with a trajectory that is profoundly modifiable by treatment. The man who accepts the diagnosis, engages with GDMT, attends follow-up appointments, monitors his daily weight for fluid retention, limits dietary sodium, engages in supervised exercise, and avoids alcohol can expect meaningfully better outcomes than the statistics for untreated or undertreated heart failure would suggest.

The most important message for men, who tend to minimize cardiac symptoms and delay medical care, is this: the symptoms you are explaining away as getting older, working too hard, or carrying extra weight might be your heart telling you it needs help. A simple blood test and an ultrasound can distinguish between those explanations. Knowing which it is matters more than almost any other clinical question in internal medicine.

The Signal Check is fifteen questions mapping the male cardiovascular risk pattern, including the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.